MEIP - Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the MEI Pharma 2022 Fiscal Year End Conference Call. Please be advised that the call is being recorded at the Company's request. At this time, I would like to turn the call over to David Walsey, MEI Senior Vice President and Corporate Affairs. Please go ahead.

David Walsey

Thank you and good afternoon everyone and thank you for joining us today. our today, ended our the June Exchange and closed the XX-K Securities market corporate Commission, year in fiscal XX, issued the we release. Form followed for and highlights After press results financial XXXX with available Both at www.meipharma.com. our of on website which are our we'll the our in summary programs business over provide On year. of fiscal the progress from call then June ended review today, last year, XX, a financials XXXX, and and

call to your will We open then the questions.

want I that Securities started, Harbor Before call may your certain fact get we the within Litigation Safe the to to of XXXX. of this contain Private attention Act provisions of the call conference Reform the forward-looking statements meeting

in its statements, based be Form expectations are filings, today. Drazba, management's XX-K discussed are aware and annual earlier introduce forward-looking you website now current our today most on to SEC Officer. our on Officer; President call should to, as A and to Gold, including risks, could uncertainties that our of contained recent a differ in number subject available conclusion. results you Dan which You those our actual Financial materially from Brian like Chief be filed speakers are after this its with and soon for to on our our I'd our Chief replay of me Executive report will

the commenting Officer Brian. your quarters. Operating summary are the well that, results as the questions. the on and Counsel; our Dan financial now as our General start Urso, for open us over with turn After remarks also Officer call before I'll and today. Chief our to coming reviewing we Ghalie, David Medical Chief Brian year line Additionally of shares with Richard will

Brian Drazba

outstanding earlier brief about XXXX our results. filed Thank I'll more $XXX our I'm information cash, in that cash provide fiscal we invite debt. detailed results a year investments pleased with equivalence regarding our and finished for Form report I you XX-K no financial review today. to short-term overview of to you, financial with our million David.

zandelisib. million XX, of XXXX. for common June our related XXX,XXX year XX, per to professional Net in $X.XX XXX,XXX operations outstanding incurred shares June overhead to related services due from We to ended of costs, year was primarily zandelisib XX, million Research primarily was expenses million The and related year. end the the increased of loss our increased revenue changes development during XX.X for for June through had increased For to XXXX. the net and for administrative General share increased were end expenses of activities. for of XXXX. increase million, year. increase in development MEI in million of million $XX.X as associated compared XXXX, prior decrease development XX, expenses for to $XX.X of XXth, corporate the and year $XX.X June to June capital. the compared XXXX, costs activity working were related XXXX, expenses year The $XX.X in XXXX, compared million support XX.X compared Kyowa $XX.X of with The $XX.X related and $XX.X compared drug personnel the costs year in clinical $X.XX or shares compared or The increased consulting June and fees increase million at to per recognized million costs, manufacturing million XXXX. trial loss net of research Kirin share to of end the cash XXX revenues XX, a general end reimbursement million the to to XXXX, was million primarily used $XX.X to stock XXXX. $XXX to

XX, June $XX.X ended adjusted year changes the for compared loss a million loss measure over the warrants, net non-cash to value XXXX, expenses the $XX.X turn call that, excluding non-GAAP Dan. our in to of was of to related for With net XXXX. I'll an fair adjusted Our million

Dan Gold

study thanks you summer. all X our Phase demonstrating first very hope rate about key half announcement follicular joining leads remission. dosed And with events for a line excited obtained least at an overall us to top the with response fiscal of starting X this Phase several COASTAL everyone the past Shortly report global was afternoon. thereafter, Brian. This in by from program, in lymphoma a of prior we which were Thanks, zandelisib I patients enjoyable study. data of marked complete patient therapy, XX.X% our two lines year had in the TIDAL

our medical seven of in subsequent encouraging to from with consistent the TIDAL meeting. that TIDAL Phase Lancet patients the It at complete now regimen. dosing administered first look at are which side published to to this discontinuation that which regimen data tolerability dosing days occur in two cycles period to and with adverse are a from Phase Xb safety first should rituximab to daily in COASTAL. an daily the TIDAL each zandelisib coincides forward for rate data Notably, the the the Grade special cut-off We X.X%. was dosing administered daily once see carry thereafter in X any plus Recall X in was as of July was being date, cycle. response continuous adverse induction evaluated the the cycles, XX-day previous zandelisib for just On experience data followed reporting that the the data forward our XX-day event once interest experience, patients upcoming patients intermittent very Oncology, to by events of tended three due consistency

patients provide provide potential the to have We patients. highly to benefit differentiated regimen to free a significant chemotherapy that should

time completed turbulent in of rather to data markets. excess announcement the gross support offering, programs TIDAL financial during $XX follow-on Following of December, in in successfully the raising current proceeds our we a a million our

an randomized designs FDA, approach cash consider Kirin, about its two Subpart type its approvals from operations And FDA MEI to to Accordingly, the adequately FDA XXXX to generally follows at to number cancer for to the acquired Project have based This support the potential such the new communicated a of The assessment as approval assess in TIDAL raise, regimens, by consider FrontRunner, PIX-kinase of tried inhibitors benefit. position years. XX an the eyes its With the of we to the and the good has and the marketing tempered the meeting, estimate of communicated our this as partner, of success early emphasized our in Despite year, of COASTAL then accelerated agency associated including meeting to this the Project Kyowa FDA study the class who've randomized on during study new MEI study addition communicated a the of generated TIDAL studies approval FDA benefit In communicated data discouraged brief, initiative thus, longer and approval At change approach with based upon they fund cancer no the based accelerated single meeting start drugs with expanded regarding approvals accelerated now submission publicly under would risk and the several past they Phase insufficient on to we drugs, that ODAC earlier access studies, sufficient Part support meeting call and planned. communicated patients in decades changes generally. was the approval single a replacing for the in FDA risk April. accelerated arm arm accelerated generally with PIX-kinase the where from March to a H. accelerated authorization. year, this on studies FDA initiative granting to efforts due approvals new to first based single continue inhibitors. X relating approach change to solely granted intent concern, our toxicity under data XXX.XXX, the rendering in a CFR ongoing X for single-arm was longstanding FrontRunner, studies. Subsequently, FDA stating our open on Phase accelerated arm ODAC other already

plan the not first single instance not Phase FDA line The support that solely the arm meeting in FDA's was agency based As announced an on to do marketing the earlier March that data. application, the TIDAL recommendation, indicated FDA with and X in would an submit to approval. the TIDAL this companies the from accelerated be with year data sufficient

TIDAL submission on to based closed While X the Phase that it in the their Phase the X efforts companies agency COASTAL did randomized study, the study. ongoing continue evaluate emphasize opportunity zandelisib the for essentially

existing continue will current XX schedule recommended, stated our addition, that support In any concerning as further appears data dosing additional zandelisib continue address reasonable, and our to any the the of our milligram intermittent dose appropriate the our we as as current we while has and regimen, schedule. of selection other efforts and consider agency to the we safety to dose evaluate ensure efforts

anti-CD-XX to chemo this Phase X In follicular of study recall, lines received Kirin. of more and to globally more the prior is in our partner or support randomized immunotherapy. is comparing you a rituximab one to marketing standard lymphomas plus relapse As applications zone Kyowa than therapy. marginal COASTAL, refractory to have the with COASTAL may patients or zandelisib or who U.S. care with intended

with been to follicular the activated believe last I of DLBCL may and and other continuing it BCL-X or enrollment with corporate are RCHOP new The August. to to eventually to factors beyond the inhibitor, we venetoclax various now push as war in in lymphoma, important COVID both worldwide, with forefront marginal timelines the other These or monotherapy impact and treatment over XXXX malignancies. our to and sites suited have add objective has combination by of focus we Thus, addition be dosed are in The combination zone meet evaluated MCL sites inhibitors ongoing while the With study pharmacological efforts closed that properties of ideally we first previously, treat to year a plus sites patient, B-cell and as our timeline. may study completing expected completion its mentioned, Ukraine, be impacted the the with XXX in used in various was although differentiating end our BTK efforts of zandelisib response anti-CD-XX, from modalities in have are has at inhibitor evaluating could patients XXXX. in our also zanubrutinib, patients PIX-kinase zandelisib CLL, respectively.

modalities immunomodulatory evaluating Finally, settings. well properties the treatment effort in we leverage in also are an in hematologic combination tumor as as of solid opportunities to other with zandelisib, combinations in potential

we progress respect program, B-cell malignancies. MYC demonstrating will and candidates X meeting, look from add you drug open medical share to AML, updating zandelisib including venetoclax Phase the ME-XXX against clinical-stage our data AML the anti-leukemic medical study, subsequently from available and which is the voruciclib study the of that a then relapsed to well conferences various the to at patients demonstrating we to our as phase that to past reported we as with voruciclib, two this well demonstrating modulating With also we Beyond forward our also data AML. enhanced on at orally as and with resistant reported of refractory now program, from where in tolerated CDK-X respect Phase With in over of months. candidate, combination updates programs signals. our identification as venetoclax the well initial enrollment patients this X activity preclinical dose data. cells We regimen, data efficacy venetoclax XX

consider exploring current further ME-XXX efforts cancer, solid focused in hematologic applications tumors. our for may on we While are

few hires Clinical team key Alejandro the this candidate the refractory our ME-XXX next Yomara From Anne People Development. as the Chief to Ricart, cancer. including Officer; into over Specifically Frese, advancing strengthened inhibitor as the phase year, President Quality; Gomez, the patients be Vice plus as course evaluate of next President corporate quarters our Avastin relapse last of we and development Vice in will perspective, in the program with with VEGF of colorectal and Senior in Senior some

single provides patient Kango remain to we in Sujay physicians Kyowa industry new agent treatment and zandelisib significant with with address or Board to added options. to medical needs we Kirin, Together experience. important to combination the ultimate potential Additionally, commercial important a who and other provide as of their the therapies committed

to deliver disappointing MEI the plans, at for important our the and that clinical and given ultimately knowledge profile While a it's I suggests positive building the patients team our along and to undoubtedly with factor position the is clinical confident course sudden that of have our and to have opportunity changing continues consistent value healthy in a and we good to FDA's a that am our getting set zandelisib this realize very our experience supports set program our partner strong program. here approach investment a shareholders. to Kirin, Kyowa cash data for

this zandelisib and year. to forward in COASTAL, We by end look of complete at advanced on we meeting we an as program As general likely follows. the quarters, the the particular plan to over provide in providing coming the medical data calendar update TIDAL upcoming updates the

DLBCL. Additionally, accompany we And valuing zandelisib of studies first look the in evaluating already we for to forward RCHOP the zandelisib plus CLL. investigator to study to rituximab and forward investigator initiated patients patients CORAL in line look certain dosing study plus the potential in ongoing additional with venetoclax the first relapse

Phase share the the end AML, calendar in year. we plan of next voruciclib in X the the with the toward On combination program patients venetoclax on an with update on at particular probably front, to

the ME-XXX the around pipeline. the the forward across program, relapsed with in and XB over look in end. the last sharing achieved year in colorectal calendarXXXX data patients proud am study the we summary, multiple our the and Phase year successes initial For initiating of quarter combination of first progress the In to the we've I and Avastin cancer evaluating

requirements open best mission for how outcomes the I can stakeholders for a FDA's Q&A. to think reconfiguration approval our the we approach by Project the best-in-class improve we novel therapies. zandelisib to of our and efforts I'll and value with achieving operator ultimate instructions necessitates, to success outline and the for of asking deliver for FrontRunner measured now patients to While then our commercialize obstacles new ask the through the overcome cancer can adoption our be and our provide program, develop call to questions, accelerated

Operator

will first Willey begin session. question our [Operator will Please the from question-and-answer come We Stifel. now Instructions] Stephen of And ahead. go

Stephen Willey

had was path that to to expeditious time ahead So, for allow going we necessarily had that a guess, Kyowa There I data you I conference primary surrounding FDA call. accelerated, might were endpoint. of engage potentially to think, last and some some approval be suggestion try a submission, not may but a

of see COASTAL? on So, than endpoint post is since FrontRunner safe it to kind final out made that primary more likely comments not say this those that it's Project pushed has now were we a FDA mandate read that,

Dan Gold

right Yes, hi, Steve. I of end up guess I was to the following question. the you

-- willing I has randomized the entertain approval. that full endpoint plan the if mean, recall our primary that based as FrontRunner, then example Project an data think I to approval you the said FDA they on and still as are final accelerated

the Project endpoint be a of continuing with final the understand an are pursue COASTAL whether is to the final for FrontRunner study. really and the efforts sort is the randomized some FDA in dialogue from could endpoint, of data primary study the PFS We this what -- used to with which filing the intended accelerated of follow-up

definitely So, do to discussions, very as with you make this the continue we those keep but I agency think posted on we that, progress we on dialogue issue. will

Stephen Willey

then follow-up. I work. FDA mandates Okay. additional maybe other just and here believe Optimus received is you of one maybe some feedback the had as project some exploration And dose regarding know a agency's desire see to I the

speak to FDA some guys plan how just Can maybe on of you addressing So is concerns/feedback? you plan that on at initiating those point? that some here something you

Dan Gold

a Yes, that's asking. question, a Steve. for really very Thanks important and it's proposed

seeing -- milligrams, start than dose lower We we done exploration what was did which we recall, were in and the at animal went a to dose XX So if safety counseled and XXX of our just to have signals XX in safety on by XXX, up no change you program. in signals. without data. importantly and much no efficacy based do change any We to

by the Further than, the dose continuous to to cut So, and we we fact moving noted again intermittent by XX% study on schedule. drop back dosing profile the down XX. doses, to in continuous continue we the toxicity as following

think we a addressed that, we FDA's of the do So concern. number have

concerned FDA learned just is that that, efficacy We think the subsequent However, we It efficacy. as and and safety. postings balance about that. FDA very from we from the done maximizing about have isn't ODAC the have between

data We well as looking from Kirin Phase set in I our large partners' the as TIDAL, studies, well now have a Mirage from study. as of Kyowa our as

are So, daily you a to We some of we which believe if may a have you we're a able think an we achieve is on balance now dose. non-efficacious exposure But with safety this association. dosing, very well dosing other robust the as get PIX-kinases, set be response as cannot intermittent that data given that the really we exposure analyzing see, for there unlike to it. achieve unless to

evaluate data milligram ways is we our And that do data. intermittent is asked say patients. final schedule work So just other But And then to to that, and just quicker on you dose, that recall, the goal studies evaluate and goal the and first that's in dosing the potential if to schedule. that be, did XX especially felt consider doing some further reasonable can in of they that justify first FDA our to have hand. the need making us dose point appeared

Operator

of The ahead. Robyn Please Truist. next comes question from go Karnauskas

Robyn Karnauskas

understand over focus call. the going zandelisib us as be well products, as XX XXX the his see your can Can at look Company? to understand you to pipeline, catalyst the on for we including of regarding our is other the of what cadence flow like outside help know help I the months for like next news me that

David Walsey

Yes, asking for it. question Thanks Robyn. that's great

as in the COVID malignancies. and with is it's it protocol. as relapsed/refractory have by voruciclib we've was FDA reported data deeply just protocol be DASH. the -- but IRBs agreement recent FDA. mentioned and shortly So, completed on or track escalation we patients now as on -- that we It the And the we in because specialty dose at first. by the now and We The expect we definitely to monotherapy requested -- ASCO very as it B-cell enrolling reported patients we at an -- AML will have I impacted say program is AML

that community our lot be AML the there of -- particular lot hope appears there is a So to a of in interest combination. this is on is

rapidly, at enrollment go coming data escalation hoping able the So, in that initial to report some least and will to from venetoclax we're that of being dose forward look the we enrollment definitely year. with the

the about out to think been I has not historically important is marrow point issue a a significant with amount there which toxicity, venetoclax CDK-X good recipe. the is probably combined inhibitors of

We seen with any significant to have that voruciclib. never degree

these question, going activity treating disease to see start at little venetoclax, it marrow the to start because but is as two drugs with So a we a hard get play information to we'll well. signals be to some if I hopefully and together AML it's some and think well tease out certainly, will of

and these samples schedule Dana-Farber, that these dose and in studies. like various that really we for David the a at where of interpret B-cell the to have with he's So, collaboration one the that from important looking be the in looking the We the do think on then completed blood actually we're I inhibition we're using profile hope the MYC combination getting that'll at of And Matt that the focusing and patients. MCLX is us help going at arm. that's from program, cohort final nonclinical markers

third at on a cooperative then in So, of to venetoclax. I we're coming in especially finally that a studies Everything that does It's in in And group information group this set we'll go. colorectal. have now think working XXX, early combination lot with. -- have line essentially particular of is the a a great we we're in case the with point year, lot of a voruciclib

lot quarter pretty patients And of so, that a with those should quickly And him. next get in these there. we'll hopeful presumably, of we're are really -- go because the treatment first month patients there's good started year. that And not available next

us for that some we So well of be data I the our rolling rich year studies near the zandelisib and future. out very be think, pipeline it's other hope going with as a in to as to

Robyn Karnauskas

one, One time the second, with think think have the in helpful. and on line, take going with in of might molecule processes How to the few requirements there are don't broad more hearing first that And too That's short, thought one that who that? how as much what points, the questions, have to seeing how up small the actually from about much for you space? the other people nine of government you you new People in are your you're big line companies up want collaborate or probably it. versus, only for number want you two this of bring face but development you about line FDA. years, the like, color you drugs act call. later question, when or changes are and in that in partners? versus Do early do development they view are the actually given you you well of instead Because I struggles midst

Dan Gold

mean, still previous interesting even -- are entrants not pull been formally at of FDA have the other that But very companies the there on We market that though many that accelerated Their ODAC that packed FDA. zandelisib approvals. problems clearly, formal certainly, had. question. the entrance the about two are there lot voluntarily mean, market. has the the the The a the the still their I of there pulled they nonetheless, approvals. of But is the concern a space is on I any presentation. certainly dialed absolutely I FDA's that it is -- concerns. think, specifically. solves think valid into mean, have and presentation is first concerns us It's I did

use always think different that heightened not emphasized all that was of on a I'm FDA didn't signals schedule. do concern, way that based the dose because I is are the drug we So we others part a chemical actually with nor our like the and other there seeing mean, entrances our class -- the class. of same We've do it drugs in of I not the

at that as evaluate down is the will to ground hope the that that's some FDA FDA some of that member up a gain laying question. alluding the we hopeful That's think with about agency the I appropriate a a to And we any with we're drug rather what other clarity So Steve's than us class. what of as new they're time. fashion, sponsors mean, I randomized line general, to encouraging but think in therapy, in especially combinations. In moving

I lot think, are molecules. going take us. it's for it's all have all our a -- of to we a And of of small time three pipeline

long, going basically So the it's design, making new rethinking it an orphan to is that to at satisfy extent. about the mandates studies so to follicular, take with we're in how playing field without least disease some these take clinical and some especially

and doing it patients challenges, up being studies for. getting what but that so big signed we And required, are does some it's provide

agency's to have how just needs. learn the accommodate we So to

Operator

Laidlaw comes next Co. of Yale from Jen question Please The & ahead. go

Yale Jen

the taking afternoon for Good and thanks questions.

with ones top that, start to is different previous line quite quarter, the three. going since from Just housekeeping number the last

new there fiscal suggestion XXXX? what for any of remaining the guidance sort So is are we for years, the starting to looking fiscal or

Dan Gold

sure I'm I'm cash the mean top-line, you Yale. what quite sorry, number? not the

Yale Jen

the is three lower, number significantly compared this and to actually, quarter the No, previous quarter revenue the negative. as

So, I'm should about we top-line kind for quarterly curious think of in fiscal just general 'XX. what

Dan Gold

really reporting is revenue our KKC. function I sharing of part reimbursements, Yes. the large cost our with a in mean, yes,

It's clinical else. of activity came revenue. mean, than we it's reflected. or up I I counted payments the don't which just a more an slows, are accounting anything in, think milestone have as that did ramps few as So treatment

the the the in reflection set with So, a reimbursements is more is way KKC. that of really up of revenue the agreement

I pretty it's unwinding COASTAL much increase up. down whereas quarter-to-quarter, either pretty or So overtime, It activities but it's clinical is decrease. is may as TIDAL fluctuate think ramping straight. consistent much our

Yale Jen

ones. great. two Okay, And quick maybe then

other we is The year full first the there or venues this Should TIDAL that of maybe the could sort data. as think one about? is we consider ASH of top-line study

Dan Gold

population treat. Well, a very the I think meeting that ASH always us, especially we patient for appropriate for is that

think like a yes. the it reasonable to meeting a top-line would data I like be So if and to it's to expect warranted final able that ASH, quite that, deems the committee at report we that value

Yale Jen

tuck-in can And one status here for then any thoughts, or this review maybe point? situations the Any a enrollment patient you at update regarding or [indiscernible] last the anything is the study. which enrollment,

Dan Gold

it, mean, I give enrollment won't well, a you in do now. we past, the clinical That's and early general, I in we have especially why most don't trial Yes. usually in numbers your right of as have can is screening open get so efforts this or patients. of sites and our the thing year. size past the where magnitude this all been they can said -- and initiate our start treating critical and That's of over majority efforts

essentially at more will 'XX. enrollment point continue in will trajectory of of continue that to will that some world are open sites. and our XXX and all objective the soon. continue completing do our open or sites, Hopefully, almost, to to end an sites over now come we we over we and open I But mentioned, grow so in As new to meet

Operator

[Operator from ahead. will And Fargo. next come Abbott Nick our Instructions] question Please of go Wells

Nick Abbott

full the do And you for when then, intention lymphoma? one of data for expect to Kyowa First approval? the data these to X Japanese report Kyowa still is from zandelisib, submit Phase trial advanced

David Walsey

I seek what their a intent that true I I'm intentions not what different their intent -- their are here. they're they that Right, doing running seek publicly their that and They they completed an -- don't Nick. that study assessments. not always enrollment and their plan to should than for do in intent sure think believe even I was know operate They that was a know what the but don't long Japan. mechanism, data. we stated their was don't Kyowa their approval but Hi. to in exactly that believe is accelerated I now, for the but announcing -- approval full are, doing timelines previously approval. a has full too have -- we in way

that And to the ready. so, it is way file to for their intent your is I is and ran full study they're all they know guess was when is question that to when do to it. file we saying best that is approval of

Nick Abbott

[indiscernible] in XX October, last they completed accrual gone clinical trials have patients.

and reasonable months in to reasonably, data of a quarter. have XX up a it's fourth the trial sort So here going they're of follow size

David Walsey

Correct. Yes.

Nick Abbott

in for that plan you the then, I or analysis FDA, FDA to And COASTAL? you you're revising is know made COASTAL a have on? Or you revising said working proposal with on discussion still statistical something

David Walsey

Right.

don't it might to don't I give you we discuss discussions a to we we It general, events. how appear, And the class particular this -- is raised because color, be know, FDA has what typically, as in concerns our in again, that little a they operationally, like but rare So, FDA. not one just our it's with acknowledge approach mortality. about are in these that the straightforward as the of depth

around a with how and So not? the lot and spent penalties get what -- statistical do the have FDA trying does time analysis very so pay our we complicated. one those of look that arms discussion the may outcomes that It's had articulating FDA taking around to forward the all look that really former letting one statisticians a or as to and can once most for are. consultants, And possible. the we've to discussions said, with we issues meaningful the We've

but timely guess I as as forward in I with going think as look deep I'm question. that that's you comfortable about possible, to fashion to will articulating that We as

Nick Abbott

this in recent And publication Thank head then That's of PIX-kinase for, me, review using dosing. neoadjuvant the Sure. but so They in for delta preclinical the and for which the was therapy neck peer use cancer. inhibitor a was obviously clinic good. there you. they is also on data were using what drug dose publication too depletion, continuously T-reg and part toxic of saw intermittent was

were many what -- zandelisib? think in of from is that do these using So data? around trial corner the scripts. these the the How intermittent new MEI repeating you around of Obviously were interested note authors authors these just of is dose

Dan Gold

Yes.

as might imagine. attention, So, it our Nick, escaped hasn't you

appointments a have particular in In fact, that of the Jolla. here authors that mentioning you're paper La are faculty

heartened because that especially dosing dosing experience. are very it in patients see seems really they to actually pretreated toxic, that important. be neck I them were be is intermittent out as less sort pointed continuous their heavily for going We And supported think who to them. know we of in too our to head So thesis

property was T-regs I as CTLA-X heartening example and dosing think PD-X in tumor in as a its with we with models and T-regs we solid of in us. B-cell appropriate do setting. setting. some, in taken think solid be on well very regulatory we in surgically preclinical work of previously, setting of delta that as T-cells tumor or scheduling advantage important where to have importance as known with done the a an that antibodies could malignancy be I And said very for inhibiting And are combination fair feel scheduling appear to bit way or have of in

to say, just think, and had that do think, is for now, I this, our about Obviously, multiple very we but I'll lose to I is in because be opportunities certainly well. facets focus This the want T-regs and homing So on we as expression, PIX of exploring is very in and it that by this significant aspect And radar. different group COASTAL, immunoregulatory interested in don't we're stay tuned. environment. micro think said, delta we I important know there

the that of zandelisib of it's situation sort the an analogous to think we advantage do that respect. very where of lenalidomide So, really possibility We want to immunomodulator. taking really in explore

Operator

the like session. turn question-and-answer I any to for back to Dan our Gold conference concludes remarks. This would closing over

Dan Gold

all again today. spent our we advance as best programs. we Thank all And you. the for coming you the and progress to the the rest with continuing do us weekend. look share time the wish forward All best. you you We of for our to of thank day And your

Operator

you now presentation Thank conference disconnect. concluded. attending The you now may and is today's for

MEI Pharma (MEIP) 9 Sep 222022 Q4 Earnings call transcript